Septerna (NASDAQ:SEPN) Insider Sells $354,647.88 in Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88. Following the sale, the insider owned 793 shares in the company, valued at approximately $23,837.58. This trade represents a 93.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Samira Shaikhly also recently made the following trade(s):

• On Monday, March 2nd, Samira Shaikhly sold 70,453 shares of Septerna stock. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30.

Septerna Trading Down 2.7%

Shares of SEPN stock opened at $30.20 on Friday. Septerna, Inc. has a 12 month low of $9.11 and a 12 month high of $32.63. The stock has a market cap of $1.36 billion, a PE ratio of -37.28 and a beta of 2.21. The company’s fifty day moving average price is $25.48 and its 200-day moving average price is $26.09.

Septerna (NASDAQ:SEPN) last announced its earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The firm had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. On average, sell-side analysts forecast that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Septerna

Several institutional investors have recently added to or reduced their stakes in SEPN. Goldman Sachs Group Inc. increased its holdings in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after buying an additional 1,260,409 shares in the last quarter. Janus Henderson Group PLC bought a new position in Septerna during the 1st quarter valued at about $21,334,000. First Light Asset Management LLC bought a new position in Septerna during the 4th quarter valued at about $17,308,000. Primecap Management Co. CA purchased a new stake in shares of Septerna during the 4th quarter valued at about $15,225,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Septerna during the 2nd quarter valued at about $5,723,000.

Wall Street Analysts Forecast Growth

Several research firms have commented on SEPN. JPMorgan Chase & Co. boosted their target price on Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Truist Financial raised their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Wall Street Zen cut shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Septerna in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Septerna currently has an average rating of “Moderate Buy” and an average target price of $43.13.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.